| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Jun―23 |
Reflections on Pending Technical and Legal Issues in the R&D of COVID-19 Medical Products |
NA LI, YUPENG DONG, XIANG YU |
| 2 |
[GO] |
2023―Sep―26 |
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine |
NA LI, YUPENG DONG, XIANG YU |
| 3 |
[GO] |
2023―May―24 |
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control |
Zhou Chen, Wu Wanqiang |
| 4 |
[GO] |
2023―Feb―02 |
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine |
Xiang Yu, Na Li, Hui Wang |
| 5 |
[GO] |
2022―Jun―07 |
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-19 |
PENG FEIRONG, MAO TIAN, CHEN JUNHUA |
| 6 |
[GO] |
2022―Jun―06 |
Regulation of Clinical Trials and Pandemic Research: Upholding Ethical Standards During a COVID-19 Crisis |
Patrick Foong, Grace Borsellino |
| 7 |
[GO] |
2022―Mar―25 |
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines |
RAILDO DUARTE, HASAN IRFAN KHAN, ALEJANDRO LUNA, RAMADAN AMIN, CHARUL YADAV, ULRICH STORZ |
| 8 |
[GO] |
2021―Mar―11 |
The Compulsory Licensing for Exploiting Patented COVID-19 Pharmaceutical Treatment: Legal Approaches of Some Arab Countries |
Tariq Kameel, Ramzi Madi, Kawthar Kayed |
| 9 |
[GO] |
2020―Nov―23 |
Amendment of China's Biotechnology Laws in Relation to the Prevention and Containment of the COVID-19 Pandemic |
Zi Zhengfa, Wu Wanqiang |
| 10 |
[GO] |
2020―Sep―28 |
UK Biotech Corporate Finance Trends Post COVID-19 |
Sunjay Malhotra, Julian Stanier |
| 11 |
[GO] |
2020―May―08 |
Continuing CRISPR Patent Disputes May Be Usurped by Its Potential Role in Fighting Global Pandemics |
Asawari Churi, Sarah Taylor |
